SYDNEY, AUSTRALIA, June 02, 2022 (GLOBE NEWSWIRE) —
Immutep
Limited
(ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, will host a global webcast to discuss new data from 1
st
line non-small cell lung cancer (NSCLC) patients participating in its Phase II TACTI-002 trial including an analyst Q&A.
The new data will be presented in an Oral Presentation at the American Society of Clinical Oncology’s (ASCO) 2022 Annual Meeting on Friday 3 June 2022 at 1:00 pm, US Central Daylight Time (CDT); corresponding to Saturday 4 June 2022 at 4 am, AEST and announced to the market.
Webcast Details
D
ate & Time:
8.00 am AEST (Sydney) Tuesday 7 June 2022 /
5.00 pm CDT (Chicago) Monday 6 June 2022
Speakers:
Immutep CEO Marc Voigt, CMO/CSO Dr Frederic Triebel and Christian Mueller, Vice President Strategic Development
Register:
https://us02web.zoom.us/webinar/register/3616539572927/WN_fAVtcc30SXuBz-kBxfF86g
Questions
:
Investors are invited to submit questions in advance via
[email protected]
.
A replay of the webcast will be available after the event at www.immutep.com.
About Immutep
Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM) and on the NASDAQ (IMMP) in the United States.
Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep’s large pharmaceutical partners.
Further information can be found on the Company’s website
www.immutep.com
or by contacting:
Australian Investors/Media:
Catherine Strong, Citadel-MAGNUS
+61 (0)406 759 268;
[email protected]
U.S. Media:
Tim McCarthy, LifeSci Advisors
+1 (212) 915.2564;
[email protected]
